Obstructive sleep apnea syndrome and cardiovascular disease: The influence of C-reactive protein

Obstructive sleep apnea syndrome (OSAS) is a common medical condition, associated with atherosclerosis and cardiovascular disease (CVD). The underlying pathophysiologic mechanisms of this association have not been completely understood and may be multifactorial in origin. A number of studies suggest...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of experimental medicine Vol. 5; no. 2; pp. 77 - 83
Main Authors Bouloukaki, Izolde, Mermigkis, Charalampos, Kallergis, Eleftherios M, Moniaki, Violeta, Mauroudi, Eleni, Schiza, Sophia E
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 20.05.2015
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Obstructive sleep apnea syndrome (OSAS) is a common medical condition, associated with atherosclerosis and cardiovascular disease (CVD). The underlying pathophysiologic mechanisms of this association have not been completely understood and may be multifactorial in origin. A number of studies suggest that inflammatory processes have emerged critical in the pathogenesis of CVD in OSAS. A range of circulating inflammatory molecules has been identified and measured, with a view to assess inflammation and predict vascular damage risk, such as plasma cytokines, adhesion molecules, and C-reactive protein (CRP). CRP is a relevant marker worthy of further study, because not only is elevated in patients with OSAS, but also is rapidly becoming a risk factor for cardiac disease. Furthermore, in selected OSAS patients, aggressive treatment of the disorder may lead to retarding or even improvement of CVD progression. However, still there is a debate on the true correlation between CRP and OSAS, as well as the clinical effect of any reduction after OSAS treatment. Further research is required to define those OSAS patients who will have a considerable reduction with treatment, as well as to understand the significance of the interaction between cardiovascular risk factor and CRP reduction in patients with OSAS.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Author contributions: All authors contributed to conception and design of the study, acquisition of data, or analysis and interpretation of data, drafted the article or making critical revisions related to important intellectual content of the manuscript and approved of the final version of the article to be published.
Correspondence to: Sophia E Schiza, MD, PhD, Assistant Professor of Respiratory Medicine, Sleep Disorders Center, Department of Thoracic Medicine, University General Hospital, Medical School of the University of Crete, Rio, 71110 Heraklion, Crete, Greece. schiza@med.uoc.gr
Telephone: +30-281-0394824 Fax: +30-281-0394670
ISSN:2220-315X
2220-315X
DOI:10.5493/wjem.v5.i2.77